First positive results from TEDOPaM Ph 2 trial announced in advanced pancreatic cancer
Silvia Comis, MD, Chief Clinical and Medical Research Officer OSE Immunotherapeutics, commented: “We are pleased to share the latest clinical updates on our cancer vaccine Tedopi® at the ASCO Annual Meeting. Tedopi® combines 10 neo-epitopes derived from five tumor antigens, selected for their presence in a range of tumors, offering a multi-target “pipeline in a product” approach for HLA-A2 positive patients to address unmet needs in oncology. The positive results for Tedopi® in pancreatic cancer are promising for this devastating disease with a poor prognosis. We extend our gratitude to the GERCOR Oncology Group and the PRODIGE Intergroup, sponsors of the TEDOPaM study, for presenting these encouraging results at ASCO. In lung cancer, patient recruitment is progressing per plan in the Artemia Phase 3 registration study, a key milestone bringing us one step closer to the registration of Tedopi® for NSCLC. As previously communicated, the readouts of the combination Phase 2 trials, CombiTED for NSCLC and TEDOVA for ovarian cancer, are expected in 2026.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000